Østergaard Mette, Stentoft Jesper, Hokland Peter
Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 C, Denmark.
Leuk Res. 2004 Nov;28(11):1213-5. doi: 10.1016/j.leukres.2004.03.011.
We have developed a real-time quantitative RT-PCR (RQ-PCR) assay for the DEK-CAN fusion transcript, which results from t(6;9)(p23;q34) and is found in about 1% of acute myeloid leukemia (AML) cases. In diagnostic samples from three acute myeloid leukemia patients an RQ-PCR assay sensitivity of 1:396-1:3446 was obtained. In a single patient followed closely for 57 weeks, an increasing DEK-CAN level was detected 40 days before an early hematological relapse. This assay should enable the widespread longitudinal minimal residual disease (MRD) follow-up in this rare subgroup of AML patients, thus adding to our knowledge of its course.
我们针对DEK-CAN融合转录本开发了一种实时定量逆转录聚合酶链反应（RQ-PCR）检测方法，该融合转录本由t(6;9)(p23;q34)产生，约1%的急性髓系白血病（AML）病例中可检测到。在三名急性髓系白血病患者的诊断样本中，RQ-PCR检测的灵敏度为1:396至1:3446。在一名被密切随访57周的患者中，在早期血液学复发前40天检测到DEK-CAN水平升高。该检测方法应能在这一罕见的AML患者亚组中广泛开展纵向微小残留病（MRD）随访，从而增加我们对其病程的了解。
